|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 14.2 0.00 0.00%
Vice President Head of Corporate Development
Mr. Stefan Fraenkel serves as Senior Vice President, Head of Corporationrationrate Development at Swedish Orphan Biovitrum AB . He joined the Company in 2009. He is also Board member of Akinion Pharmaceuticals. He was Management Consultant and has held several international managerial positions within Wyeth Pharmaceuticals 20012009
Age: 43 MBA
46 86 97 20 00 http://www.sobi.com
Fraenkel holds a Doctorate of Philosophy degree in International Accounting and Management. Apart from that, he has obtained a MBA degree from Copenhagen Business School and a BS degree in Engineering from Chalmers Tekniska Hogskola.
The company has return on total asset (ROA)
of 8.0 %
which means that it generated profit of $8.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 5.6 %
meaning that it generated $5.6 on every $100 dollars invested by stockholders.
The company has accumulated 53.55 M in total debt with debt to equity ratio (D/E) of 0.09 which may suggest the company is not taking enough advantage from borrowing. Swedish Orphan Biovitrum AB has Current Ratio of 1.74 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.